SG11201700071WA - IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF - Google Patents

IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Info

Publication number
SG11201700071WA
SG11201700071WA SG11201700071WA SG11201700071WA SG11201700071WA SG 11201700071W A SG11201700071W A SG 11201700071WA SG 11201700071W A SG11201700071W A SG 11201700071WA SG 11201700071W A SG11201700071W A SG 11201700071WA SG 11201700071W A SG11201700071W A SG 11201700071WA
Authority
SG
Singapore
Prior art keywords
mutein
amyloid
amino acid
acid sequences
products based
Prior art date
Application number
SG11201700071WA
Other languages
English (en)
Inventor
Stefan Barghorn
Heinz Hillen
Andreas Striebinger
Simone Giaisi
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of SG11201700071WA publication Critical patent/SG11201700071WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
SG11201700071WA 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF SG11201700071WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021308P 2014-07-07 2014-07-07
PCT/EP2015/065362 WO2016005328A2 (en) 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Publications (1)

Publication Number Publication Date
SG11201700071WA true SG11201700071WA (en) 2017-02-27

Family

ID=53525183

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700071WA SG11201700071WA (en) 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Country Status (11)

Country Link
US (2) US20160000891A1 (enrdf_load_stackoverflow)
EP (1) EP3166969A2 (enrdf_load_stackoverflow)
JP (3) JP2017532289A (enrdf_load_stackoverflow)
CN (1) CN107074924A (enrdf_load_stackoverflow)
AU (2) AU2015286824A1 (enrdf_load_stackoverflow)
CA (1) CA2954031A1 (enrdf_load_stackoverflow)
IL (1) IL249925B (enrdf_load_stackoverflow)
MX (1) MX2017000094A (enrdf_load_stackoverflow)
RU (1) RU2750268C2 (enrdf_load_stackoverflow)
SG (1) SG11201700071WA (enrdf_load_stackoverflow)
WO (1) WO2016005328A2 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101906161B1 (ko) 2005-11-30 2018-10-11 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
MX336196B (es) * 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2016005328A2 (en) * 2014-07-07 2016-01-14 AbbVie Deutschland GmbH & Co. KG IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF
CN117054645A (zh) 2016-09-06 2023-11-14 富士瑞必欧株式会社 甲状腺球蛋白的测定方法及测定试剂
US11802867B2 (en) 2016-09-13 2023-10-31 Fujirebio Inc. Cardiac troponin assay method and assay reagent
WO2020046793A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN110412294B9 (zh) * 2019-08-07 2023-05-26 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN112851786B (zh) * 2019-11-12 2022-11-15 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
JP2024505081A (ja) * 2021-01-28 2024-02-02 エイブレイン 神経変性疾患を治療するための遺伝子療法
EP4230645A1 (en) * 2022-02-22 2023-08-23 Technische Universität München Peptidic inhibitors of amyloid self- and cross-assembly
CN117700525B (zh) * 2024-02-05 2024-06-18 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DK1954718T3 (en) * 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
CA2730804A1 (en) * 2008-07-25 2010-01-28 Abbott Laboratories Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses
MX336196B (es) * 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (en) * 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2016005328A2 (en) * 2014-07-07 2016-01-14 AbbVie Deutschland GmbH & Co. KG IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Also Published As

Publication number Publication date
US20160000891A1 (en) 2016-01-07
WO2016005328A2 (en) 2016-01-14
WO2016005328A3 (en) 2016-05-26
AU2021200575A1 (en) 2021-03-04
RU2750268C2 (ru) 2021-06-25
AU2015286824A1 (en) 2017-02-09
MX2017000094A (es) 2017-04-27
IL249925B (en) 2021-09-30
BR112017000428A2 (pt) 2017-10-31
RU2017103527A (ru) 2018-08-07
US20240075114A1 (en) 2024-03-07
JP2021001203A (ja) 2021-01-07
JP2023036606A (ja) 2023-03-14
CN107074924A (zh) 2017-08-18
IL249925A0 (en) 2017-03-30
EP3166969A2 (en) 2017-05-17
JP2017532289A (ja) 2017-11-02
RU2017103527A3 (enrdf_load_stackoverflow) 2019-02-19
CA2954031A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
SG11201700071WA (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF
IL286265A (en) A new tilapia virus and its uses
AU2016298394C1 (en) Ancestral virus sequences and uses thereof
ZA201701851B (en) Fmdv recombinant vaccines and uses thereof
SI3197472T1 (sl) Rekombinantni proteini brez PHE za uporabo pri zdravljenju fenilketonurije
IL251571A0 (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
EP3215172A4 (en) Modifications and uses of conotoxin peptides
IL252902A0 (en) Amino acid and peptide conjugates and their uses
IL287985A (en) A peptide derived from koc1 and a component containing it
EP3199543A4 (en) Novel peptide and use thereof
IL258056A (en) Foxm1-derived peptide and a component containing it
GB201404569D0 (en) Cyclopropene amino acids and methods
IL251289A0 (en) New peptide derivatives and their use
EP3325499A4 (en) Novel peptide and use thereof
AP2016009565A0 (en) Immunogenic peptides of ebola and applications thereof
EP3209697A4 (en) Fn14-binding proteins and uses thereof
EP3178837A4 (en) Urlc10-derived peptide and vaccine containing same
EP3178839A4 (en) Cdca1-derived peptide and vaccine containing same
SG11201610918RA (en) Peptides and uses thereof
IL258107A (en) Peptide derivative - mphosph1 and a component containing it
HK1241861A1 (en) Amino acid and peptide conjugates and uses thereof
HK1257010A1 (en) Fcv recombinant vaccines and uses thereof
HK1237795A1 (en) Novel peptide derivatives and uses thereof
AU2014902031A0 (en) Immunogenic vaccines and uses thereof